



SENESTECH, INC.  
NASDAQ: SNES



## First Quarter of Fiscal Year 2017 Financial Results

Thursday, May 11, 2017  
5:00 p.m. Eastern

### CORPORATE PARTICIPANTS

**Dr. Loretta Mayer** - Chair, Chief Executive Officer and Co-Founder, SenesTech, Inc.  
**Tom Chesterman** - Chief Financial Officer, SenesTech, Inc.  
**Robert Blum** – Managing Partner, Lytham Partners

### PRESENTATION

#### Operator

Good day and welcome to the SenesTech First Quarter Fiscal Year 2017 Conference Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star "\*" key followed by zero "0." After today's presentation, there will be an opportunity to ask questions. To ask a question you may press star "\*" and then one "1" on your telephone keypad, to withdraw your question, please press star "\*" and then two "2". And please note this event is being recorded.

And now I would like to turn the conference over to Robert Blum. Please go ahead.

#### Robert Blum

Thank you, Ryan and thank you all for joining us to discuss SenesTech's first quarter fiscal year 2017 financial results for the period ended March 31, 2017 and corporate update conference call. With us on the call representing the company today are Dr. Loretta Meyer, Chair, Chief Executive Officer and Co-founder of SenesTech. and Tom Chesterman the company's Chief Financial Officer. At the conclusion of today's prepared remarks we will open the call for a question and answer session.

Before I begin with prepared remarks we submit for the record the following statement. Statements made by the management team of SenesTech during the course of this conference call may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21 E of the Securities Exchange Act of 1934 as amended. And such forward-looking statements are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995.

Forward-looking statements describe future expectations, plans, results or strategies and are generally preceded by words such as may, future, plan or planned, will or should, expected,

anticipated, draft, eventually or projected. Listeners are cautioned that such statements are subjected to a multitude of risks and uncertainties that could cause future circumstances events or results to differ materially from those projected in the forward-looking statements including the risk that actual results may differ materially from those projected in the forward-looking statements as a result of various factors and other risks identified in the company's filing with the Securities and Exchange Commission.

All forward-looking statements contained during this conference call speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. The company does not undertake any obligation to publicly update any forward-looking statements whether as a result of the receipt of new information, the occurrence of future events or otherwise.

With that said, let me turn the call over to Dr, Loretta Meyer, Chair, Chief Executive Officer and Co-Founder of SenesTech. Loretta...

#### **Loretta Mayer**

Thank you, Robert and good afternoon to all of you out there on the line. We appreciate you taking the time to join us for today's call. As a recap, since our EPA approval in August of 2016, I'd like to give just a high level of some of the accomplishments and achievements that we here at SenesTech have seen as we carve this path to our commercial success. Probably the most momentous achievement for our Company has been the EPA approval for the registration of our first product ContraPest. ContraPest is an innovative product that uses fertility control to address the challenges of rodent management not only in the United States but globally and I do want to say, that that registration was extraordinary, it was one of the fastest the industry has ever seen and I want to continue to help folks understand that it is a dynamic registration. What that means is that registration will continue to grow as we provide additional data to the agency and as we add new species. I will talk a little bit more about that in a minute.

I think the other thing is we have really been fortunate with our treatment in the Press. Early articles by The Guardian, and Wired, and people who are very interested in a different way of managing rodents have put themselves forward and that has stimulated a public response to us that helps us to understand our market segments. And that public response is showing a very strong desire for this new product. And as evidence of that desire, since that EPA approval, we have received over 350 inbound inquiries. They are non-solicited inquiries. I'd like to say that we are truly excited about that, managing that but it also allows us to get an insight into a market segment and different strategies within that market that other rodent pest products have never seen.

In order for this company to move forward, we chose to finance it with an initial public offering and that was completed on December the 8th of 2016. We are now in that exciting time as SenesTech pivots to commercialization and the commercialization of our first product includes our sales and manufacturing distribution and I do however want to pause briefly here to put a date out there, so that we can keep it in perspective that what we are talking about our commercialization achievements that have been launched since January 23rd which was about the time that we dissolved our partnership with Neogen for both companies to move forward. Since that time, it has been very exciting. The growth has been exponential and we are now in the place of meeting the demand, building upon those first early calls.

Now, in this last 90 days we have expanded our sales force, and I know this is at the absolute foundation of the success of launching any product and in order to do that we have engaged a regeneration company. We have added seven field support marketing sales and product managers to our staffing here. We have completed the development of our sales process and that sales process includes how we manage our inbound calls, how we collect the data on those inbound calls, how we include our systems of response to our customers, with our customer relationship manager. And just to give you a little flavor of what we are doing here, we are receiving anywhere from three to five unsolicited calls a day. Prioritizing those inbound inquiries is one of the challenges and exciting tasks as far as I am concerned to make certain that we are meeting our demand in geographic and sector-specific ways, that is to say, we are giving top priority to those customers who are averse to using poison.

Now, just to give some background color there, what I am talking about is I am talking about customers who have to deal with wild animals and that's whether they are live animals that are in the sanctuary, a reserve, zoos or research facilities. These folks have not been able to use poison and we are very happy to be working with them.

Other areas, organic farms, these are places that are very critical and I'll talk a little bit more about that later. As we're moving forward and looking at the data which informs us of our market segments and our sales teams are collecting by survey, they meet these customers to take the voice of the customer and make it right up front for us to make sure we are meeting their demands and that they are in the right priority too. We are really creating a model system and in this model system surrounding rodent control needs we have selected a project that we call Project Arizona and we are rolling out in a very pinpointed fashion outbound costs these are in addition to those 350 inbound, yes, some of them are from this region, but I want to, really take just a moment to talk about what we are doing here in our sales planning.

When you look at Arizona, it is obviously a choice that encompasses a tremendous amount of livestock opportunities. We have been quite surprised at some of the livestock opportunities before us. We have over 75 feed locks. These are areas where grain in storage is stored and wherever you store grain the rats are really happy to have that address. And we are also encompassing those large urban areas, Phoenix is a large urban area, their battle however with rat of a different species, they battle *Rattus rattus* or the black rat. Some call it the roof rat, but their damage, their infrastructure damage and what they are up against is not unlike the rats that we are battling in New York City, just those are *Rattus norvegicus* or the wharf rat as you may call and they are primarily in our subterranean areas such as subways and under housing projects that we are targeting.

There is one last thing that I want to bring forward about why we selected Arizona as a domestic project to begin with, to build this model, are the climate zone. We have seven of the nine global climate zones here in Arizona, no, I am not speaking to you from a location that's over 100 degrees, we had snow day before yesterday. So, you go from the desert to the mountains, you go from forested areas to preserved bird sanctuaries and it incorporates all of those segments that we are addressing. And it allows us to work with those early adopters of our technology.



In order to do this, it is absolutely critical for the commercialization plan that you can meet the demand of manufacturing of the product and just three days ago we received our second line which allows us to double our manufacturing capacity that will be online as of the middle of next week allowing us to increase filling our orders and shipping from here.

Our current product shipments have begun and we are supplying as most of you know, municipalities, commercial, professional pest control operators. Covering these three segments, we are also expanding into the animal facilities that I discussed earlier.

As you know, when Tom and I were out on the IPO road show, we put before you the market segments that we were looking at and a very important distribution piece of that segment is to work with pest control operators.

This has another component that we are engaged in right now and that is a product learning cycle. This is where we learn how those operators are deploying our product, they have extensive experience and the learning feedback to us has been extraordinary.

We have proposals before us that we are now in a place to address which expands on those animal health facilities, the zoos, the sanctuaries, protein production facilities. These are all early adopters of this technology. The other segment that we spoke to you about are island ecologies and these are very critical to us and they are ecologies where you deal with the rodent that has a little bit different damage pattern than destroying a switching room up in New York City public station. These animals are pests. They re the same rodent pests that we meet throughout our market segments but they are destroying native flora and fauna, they prey upon native birds, they completely disrupt the ecology of an island and we are very excited that we've been selected by the Oahu Army Natural Resources Program and I approved the site location just this past Wednesday and we will be providing them with the product to address over-population of rodents on the island of Oahu.

Now what's really important about this is that they have over 10 years of data and one of the things they brought to us is that with the changing climate that is increasing water from rainfall, increasing temperatures there on Oahu the native strawberry guava is now fruiting in three times instead of two. More food, more water, more rats and we are giving them a hand there on this project. This is a very exciting one and we will be following up with that project later on.

We are also working with; remember I mentioned organic farms. Organic farmers do not use poison or pesticides. We are starting a project that will center around chicken egg production that will also be on an island and that is Bainbridge Island in the Pacific Northwest.

As we address these segments, we are also expanding our label and this is something that I do want to take a moment on to help folks understand. With our label, we received it very rapidly and we were invited by the EPA to submit data sets for changes to that label. We received our very first label change and that was a change which reduced the risk category.

Now, as just kind of an aside, personally I feel very vindicated by this label because I have been recorded on numerous television channels tasting the bait myself. So, you will be happy to know it is absolutely harmless. The only harm that remains on our label is a dermal exposure and that exposure



just requires if you are exposed longer than four hours to wash it off. That is the only restriction as to handlers' exposure.

Now, this is very important for our work in Hawaii because these products are being deployed in remote areas. The product is being dropped in on pallets by helicopters. Handlers have to hike in, it's arduous and it's nice. They don't have to hike in with all of the personal protection that would have been required under that initial label. They are very excited about having that. Now, I told you earlier that the EPA label was a dynamic label, so what that means is that we will be looking at changing the deployment areas for that.

Currently, we have indoor registration and within one foot of a structure, we will be expanding that to a full outdoor. This allows for deployment in areas such as agriculture areas or on some of these islands. We will also addressing on it restricted use. We went with a restricted use label which requires a license test control operator or certified individual to put it out. That's because we want to make sure we learn about this product, that it's deployed correctly and then we will be able to expand its use and inform the public.

We will be moving toward removing that restriction as we establish more use in our market segments. Now, I know that's a lot to absorb, but I think now it's time for us to absorb some of our financial information. I would like to turn that over to Tom and I would like to ask Tom Chesterman for a review of our financial results, then I will return to discuss some of our recent corporate developments and initiatives going forward. Tom...

#### **Tom Chesterman**

Thank you, Loretta, and thank you to everyone on the call today. Since the copy our financial results is included in the press release issued this afternoon, I will limit my comments to a few key areas. As Loretta mentioned, we took over commercialization efforts at the end of January and began implementing our sales and marketing strategies and ramping up manufacturing efforts. Therefore, we generated minimal revenue during the first quarter, less than 10,000 from product sales to certain trial sites.

As many of our potential customers need further information and some early adopters prefer to try to it on a limited basis before they make an overall commitment, we do not expect to generate materially increased revenue from the sale of products until the second half of 2017. Operating expense for the quarter was \$3.5 million compared to \$2.4 million for the first quarter of 2016. Operating expenses for the first quarter included noncash equity compensation of 1.1 million.

The increase in operating expense was attributable largely to the commercialization activities undertaken after January 2017. As I mentioned, approximately 1.1 million of the operating expenses during the quarter were noncash. We have included a reconciliation of these items in our press release. Therefore, our operating cash burn which we refer to as adjusted EBITDA during the quarter was approximately \$2.3 million or about \$750,000 per month. We expect this number to remain at this level until revenues begin to ramp up.

On the balance sheet, a couple of key points, first we ended the quarter with 8.3 million in cash, cash equivalents and highly liquid investments. We believe this when combined with anticipated revenues



is sufficient capital to successfully launch ContraPest in North America given our prudent cost structure and revenue ramp expectations. We now have 10.2 million shares outstanding and with only about \$100,000 of long-term debt, we have a very clean capital structure. We have begun to use lease financing in our capital purchases so we do expect a little more debt over the coming quarters. With all that said, let me turn the call back over to Loretta.

**Loretta Mayer**

Thank you, Tom. What to expect over the remainder of this year? We are commencing the execution of our sales plan and that sales plan nested within our overall business plan will bring further announcements from our work in New York City. New York City is an area where we are beginning as we have said before with a coordinated project in the New York housing Authority. Those shipments should be going out later in this quarter so you will see that and we will walk you through as it happens. We will also report how the success of that deployment is coming out. As Tom mentioned, this try it and buy it, so 2017 is our try it, 2018 I'd say you could consider that our buy it. Although, we do have some customers that we are working with right now who will probably be on the very short try it and buy it circuit because they've never had the opportunity to control rodents with a product like ours.

As project Arizona is rolled out, we will be reporting that to you not only by the overall success of the regional launch but also by these market segments; again, Arizona will allow us to build a model to replicate in geographic sales distribution areas. Hawaii is definitely the leader for our island ecology, and I think that you will be looking to see some exciting news from Hawaii and we will be rolling out everything that we are doing in that large project on Oahu. It is also to be expected that we will be following on with additional EPA label amendments. In closing, I really want to touch as I always do when given the opportunity to talk about this project, on the revolutionary nature of this product.

When you have a paradigm shifting project such as this, there are expectations that you have and it is always a good feeling to see those expectations fulfilled but there are also surprises and this is where you will be finding new markets as we are that we never expected to be there and that says to me that the public has a demand for this, it's the right product and it's moving us forward and hopefully moving our entire industry forward to look at a new way to solve a very old problem.

And with that said Ryan, let me turn the call over for any questions.

**QUESTION AND ANSWER**

**Operator**

Thank you ladies and gentlemen, we will begin the question and answer session. To ask a question, you may press star "\*" then one "1" on your telephone keypad. If you are using a speaker phone, please pick up your handset before pressing the keys, to withdraw your question, please press star "\*" and then two "2." At this time, we will pause momentarily to assemble our roster.

Our first with a question is Charles Haff, with Craig-Hallum Capital Group. Please go ahead.

**Lucas Perinowsky**

Yes, this is Lucas Perinowsky on for Charles Haff. And we have a couple of questions here. First off,



could you elaborate on the revenue that we saw on the income statement this quarter? Did that come from those PCOs in Louisiana and Washington State that you mentioned on your previous call?

**Tom Chesterman**

Yes, this is Tom. They were included in that; there were a couple of other minor orders that we also received.

**Lucas Perinowsky**

And is there anything you could tell us about those other orders like what types of customers they were?

**Tom Chesterman**

Well, as we said before, we've had orders and are talking people on the municipal side as well as a pest control operator. And those are the other two segments that we have got so far.

**Lucas Perinowsky**

Okay. And Summerville, Massachusetts has anymore progress been made there? Do you have any updates?

**Loretta Mayer**

In Summerville, what we are doing is we are working with that data right now. And we have a PCO in Massachusetts that we are working with and we will be moving forward in Massachusetts with this product based upon our successes in Summerville.

**Lucas Perinowsky**

Okay. And then, you have mentioned in the past that there was a large national PCO that was testing the product, I believe you said in a zero poison tolerance environment. Do you have any updates there?

**Loretta Mayer**

We are moving forward with that project. I can tell you it is in full swing. We are getting feedback from them on a weekly basis. Tom and I will be meeting with them later in June to review that project, it is moving forward as planned. And stand by is what I would say Lucas.

**Lucas Perinowsky**

Okay. Yes, I think that's all I have for now.

**Operator**

Our next question comes from Gerry Sweeney with Roth Capital. Please go ahead.

**Gerry Sweeney**

Good afternoon Loretta and Tom. How are you?

**Loretta Mayer**

Fine.



**Gerry Sweeney**

I wanted to touch back on the PCO you talked about you are starting to get some information back, the learning cycles etcetera. Anything material coming out of it in terms of changing go to market strategy or anything we can glean from there?

**Loretta Mayer**

Nothing that I can see at this point, most of what we are getting is that early learning of actually handling the product, but I don't have anything material that we can share. We haven't discovered some fancy new bait delivery yet, but we will keep you posted.

**Gerry Sweeney**

Okay. And then, just speaking on the handling obviously I mean the expectation and clearly your expectation was that the label was going to be improved. Since that happens does any material change in terms of the testing for the PCO or is it sort of baked into the process as you are testing?

**Loretta Mayer**

Well, when you have a label changer like that we let them know we were expecting it. It's a reduction in their personal protection equipment that they would need to use. And you know that all falls into their policy arena and their training strategies. When that label was changed and new product will be shipped as the new labels are printed it will be up to them if they want to make any changes. I cannot speculate because I am not a pest control operator.

**Gerry Sweeney**

Got it. And then, just sticking with some of the I guess registrations etcetera, obviously I think you talked about Europe, going after some one-off opportunities, any update on that front?

**Loretta Mayer**

Yes, we are still pursuing in Europe, I had conversations with officials in France, the City of Paris, they are struggling and I know our teams have met with some needs out of Norway. I think we are moving forward there and I don't have anything other than those two, but they are on track.

**Gerry Sweeney**

Okay, perfect. And then, just one more question I think this would be for Tom. It sounds like you are building up the sales and marketing team, product manager, I think you said 7, you have hired 7 people. Is that about the size that you need to go forward for the time being or are you looking at any more sort of significant hires.

**Tom Chesterman**

On the sales and marketing team there are still a couple of vacancies that we are trying to fill, particularly around the sales as we begin to move forward and the sales support area. There are a couple more that we probably will be adding. Those are the open recs we have right now.

**Gerry Sweeney**

Okay. I will jump back in queue. But congratulations, it sounds like you are getting a lot of traction in various spots, so, lots of interest so....





**Tom Chesterman**

Thank you.

**Loretta Mayer**

Thank you.

**Operator**

And the next question today comes from Peter Castellanos with Glacier. Please go ahead.

**Peter Castellanos**

Hi, this is Peter Castellanos with Glacier partners. Is there anyway, I'd like to try to understand a little bit about what volume goes out the door. Do you have the shipments like every week, or every month? I recently got an idea what kind of volume goes out of there. I know you have no revenues but....and a lot of the stuff I guess is not, it just goes out on spec. Can you just, I'm just trying to get an idea what the re-up might be there?

**Tom Chesterman**

Yes, thanks for that. Let me clarify, we don't have a lot going out on spec. What we have instead and what our customers are really asking for is, well, let's try one building first rather than all the buildings, or let's try one area first, before we try all of the other areas. When we say try it, they maybe getting as few as two or as many as six or even more bait stations at a time to just focus on one little area, before they make their decision for a full rollout. It is....they are very shipments going out at the offset, there will be some larger ones coming along but they haven't happened quite yet in the first quarter.

**Peter Castellanos**

Well, how many....all right. That's good, okay. How many bait stations did you sell last month, how many bait stations went out last month?

**Tom Chesterman**

Well, I don't know the exact number offhand, but we sell them, the retail price for them is approximately \$100 per bait bait station, tilled.

**Peter Castellanos**

So, if I backout, if I take the revenues and I go \$100 a bait station then I get, I get the number of the unit volume?

**Tom Chesterman**

You're going to be pretty close.

**Peter Castellanos**

Okay. In the quarter before do we revenues in?

**Tom chesterman**

No, we did not. We began commercialization in January.



**Peter Castellanos**

Well, it seems like I heard you at Roth a couple of years ago and you were putting stuff in the New York subway wasn't...weren't those commercial sales or was I just imagining that?

**Tom Chesterman**

No, those ones...those past ones were all trials that we were undertaking for submission to the EPA prior to our product registration. We had one project for example in the New York subway system that was a trial and that trial was a fixed time trial, it was a 12-week trial, which then terminated and we submitted that as part of our EPA package.

**Peter Castellanos**

So, is that subway...are we still shipping to those guys? What happened to that one? Well now it's the housing authority, but what happened to the subway guys?

**Tom Chesterman**

Yes, well what happens is that for all of those trials, they are done it's a specific trial and it must terminate and so that now there are no continuing shipments to that. That said, we continue working with New York right now as we have talked about before including the subway system to talk about exactly how the rollout is going to occur and it isn't just the subway but as you noted, there are other agencies involved as well.

**Peter Castellanos**

That just seems like a long trial. Can you give us an idea how many bait stations do you think I mean give us an idea what's the ramp, you mentioned earlier in your conversation, is that the ramp we are going to have an idea that we are going to give you some idea of a projected ramp up or I don't want to put words in your mouth, but I think the word ramp was used and what it looks like going forward and can you give us an idea what that ramp looks like in terms of the number of bait stations?

**Loretta Mayer**

Well if I could Pete. This is Loretta, just let me jump in here on why it seems like a long ramp in New York and then I'm going to toss it back to Tom. We did that work in New York City with a grant from the National Institute of Health. We collected that data to then submit the registration. We could not ship or sell anything to the MTA until we had registration. Then to complicate that to another step as only a government agency can, you have to have registration from the City of New York. The MTA could not even submit their request for proposal until we had New York City registration. If you go from August to New York City registration in February to their drafting of the request for their proposal, it puts us right on target to be looking at New York City sometime later this summer.

That's what happens with a trial that is pre-registration and I think that's one of the things that makes that registration stake in the ground so important to us. But your other question, Tom, yes?

**Peter Castellanos**

Just a ramp up, just the idea. Can you give us a number; give us an idea on the ramp up, the number of bait stations going out?



**Tom Chesterman**

Yes, we are not going to provide any guidance on specific numbers of bait stations going nor revenue guidance at this point. What I said earlier is that we are in the try it part of try it and buy it and we do not anticipate material revenues to begin to get booked until the second half of this year. We are not at this point providing any further guidance because frankly it's too early in the try it & buy it cycle to give specific guidance.

**Peter Castellanos**

Okay. Thank you.

**Operator**

And next we have a follow-up from Gerry Sweeney with Roth Capital. Please go ahead.

**Gerry Sweeney**

Hi guys. Thanks again. Just a quick follow up on the labeling on for outdoor use. If my memory serves correct, that was going to be a multiple month process and also could you remind me does that require a new application or just an amendment and then how long generally does it take after submission.

**Loretta Mayer**

Right. It is a multi-month process. We will be beginning those discussions on July 16th with the EPA and much of the data that is being collected in Hawaii right now will be used for that outdoor submission. But you are right on schedule with that, so I will be more informative after the meeting in July with the EPA as we all sit down now and decide what they are going to want from us for a final data step.

**Gerry Sweeney**

And then, would...I mean, that changes the dynamics I mean, it goes to a PCO, would still have to supply the product or manage it correct? For outdoors?

**Loretta Mayer**

A PCO or any certified personnel. For example, in the City of Chicago, all of their personnel are certified. They don't need a PCO, on Oahu in the army preserve they do not need a certified PCO to put it out. There are some differences but as I mentioned, we will be looking at lifting restricted use and going to a non-restricted use product.

**Gerry Sweeney**

That was a couple of years out though.

**Loretta Mayer**

Yes, again Gerry, there is a lot of learning here.

**Gerry Sweeney**

Sure.



**Loretta Mayer**

We've got customers coming to us that we didn't expect and if they have needs and they have personnel that can put the product out, we may accelerate our requests. We just don't know that and it would be premature for me to say oh yes we are going to remove it in two years; we are going to remove it next year. I can't say that yet, we have to learn more.

**Gerry Sweeney**

That's fair and I appreciate it especially understanding the whole process and what's being the input to it. So, thanks again. I appreciate it.

**Operator**

And again, if you have a question please press star "\*" and then one "1" and at this time. I would like to check in with Robert Blum for any additional questions.

**Robert Blum**

Yes, just one question that hasn't been addressed yet that was sent in here. This is to Loretta, can you comment on the recent public healthcare crisis in Hawaii about the lungworm?

**Loretta Mayer**

Okay. Someone is reading the New York Times carefully. Yes, we have always been instructive and try to help people understand that rodents are a disease vector. Lungworm is an infection that rodents in tropical areas are susceptible to, is present in over 30 countries around the world; I have dealt with lungworm in Indonesia in some of our early work. In Hawaii, as I had mentioned before, with the changing of climate, water, strawberry guava and other plants, rodent reproduction has increased.

Rodents in Hawaii are infected with lungworm as they are in many tropical regions. This is a challenge because the rodent then excretes the parasite and snails and slugs then consume it. They are now infected and then they crawl upon fruits and vegetables and this is where organic farms are really meeting a problem. Then from that produce it then is transmitted to the humans. Hawaii has seen an increase, they have dealt with this for many years but they are now seeing an increase in the number of cases and whenever you have a disease as difficult as this when it's like an eosinophilic meningitis. It presents with some aches, some pains some backaches, but then the only way to diagnose it in human is through its final tap. It gets very complex and it is often fatal.

We have been contacted by the government in Hawaii and we have offered to provide our services. Our teams will be returning there next week and I don't want to sit here and say we have the silver bullet. But we do have a product organic farmers can use and we can reduce the population of those rodents, which thereby reduces the incident of exposure to that disease. I hope that answers the email question.

**Robert Blum**

Ryan, any additional questions?



**Operator**

We are currently showing no further questions.

**CONCLUSION****Loretta Mayer**

Well, I thank you all for the time you've spent with us today. Many of you I expect to see at our Annual Shareholder Meeting next week and as a reminder to the investment community we will be presenting at the upcoming B. Riley Conference in Los Angeles and on May 24th, we will be presenting at the Craig Hallum Conference in Minneapolis and on the 31st we will also be in New York coming up on June 1st and if you want to contact Robert Blum, I'm sure he can arrange a meeting for us and we look forward to visiting with many of you real soon. Thanks again for everybody who has joined us. We look forward to speaking with you again in mid August at the conclusion of our current quarter. Thank you.

**Operator**

And ladies and gentlemen, the conference has now concluded. Thank you for attending today's presentation. You may now disconnect.